OncoSil™
At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo.
We believe in our technology and its ability
to have a truly positive impact in Oncology.
Latest news
MDR Approval received for OncoSil™
Read more ...
G-BA Approval received for OncoSil™
Read more ...
Comparative Analysis Indicates Benefits from
Read more ...MDR Approval received for OncoSil™ ...
Read more ...G-BA Approval received for OncoSil™ ...
Read more ...Comparative Analysis Indicates Benefits from ...
Read more ...Investor Resources
At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.
OncoSil 2022 Annual Report
ASX: OSL
References:
1. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
Want to learn more?
OncoSil™ is a brachytherapy device that utilises targeted intratumoural placement of Phosphorous 32 microparticles, delivered via ultrasound-guided endoscopy.
